Melissa A. Yates

Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial

Magdy Selim, Lydia D. Foster, Claudia S. Moy et al. · The Lancet Neurology · 2019 · 239 citations · Full text

Thrombosis, Reperfusion Injury, Deferoxamine Mesylate +11

Cutting Edge: OX40 Agonists Can Drive Regulatory T Cell Expansion if the Cytokine Milieu Is Right

Carl E. Ruby, Melissa A. Yates, Daniel Hirschhorn-Cymerman et al. · The Journal of Immunology · 2009 · 161 citations · Full text

Adaptive Immune System, T-regulatory Cell, Immune Regulation +22

Progesterone treatment reduces disease severity and increases IL-10 in experimental autoimmune encephalomyelitis

Melissa A. Yates, Y Li, Peter J. Chlebeck et al. · Journal of Neuroimmunology · 2010 · 118 citations

Inflammation, Cytokine, Autoimmune Disease +9

GPR30, but not estrogen receptor-α, is crucial in the treatment of experimental autoimmune encephalomyelitis by oral ethinyl estradiol

Melissa A. Yates, Yuexin Li, Peter J. Chlebeck et al. · BMC Immunology · 2010 · 72 citations · Full text

ATRIAL FIBRILLATION AND STROKE IN ELDERLY HOSPITALIZED PATIENTS

A. S. TRESEDER, B. S. D. Sastry, T. P. L. Thomas et al. · Age and Ageing · 1986 · 71 citations